drugset / Trial / NCT01985555
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of volitinib administered to patients with locally advanced or metastatic solid tumors and determine MTD (Maximum Tolerated Dose) or RPTD(recommended Phase 2 dose).
Timeline
- Start
- 2013-05
- Primary completion
- 2019-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Savolitinib | Small molecule | 400 mg | — |
| Subject | Savolitinib | Small molecule | 500 mg | — |
| Subject | Savolitinib | Small molecule | 600 mg | — |
| Subject | Savolitinib | Small molecule | 800 mg | — |